spacer
home > ict > autumn 2018 > quality upkeep
PUBLICATIONS
International Clinical Trials

Quality Upkeep

To ensure a smooth transition from the pre-authorisation to the post-authorisation phase of the lifecycle of a medicinal product, the marketing authorisation (MA) applicant is responsible for ensuring a robust pharmacovigilance (PV) system is in place to monitor patient safety once the product is on the market. During clinical trials, patient exposure is limited and closely monitored, and very specific criteria must be met for patients who are eligible to take part in the study. However, once the product is on the market and more widely available, patient exposure will be much more widespread and patients may experience adverse reactions (ARs) that have not been observed previously in a clinical trial setting.

To maintain compliance with EU post-marketing regulatory requirements, the MA holder (MAH) must ensure that the following are in place:

• PV systems (including appropriate technology, quality management system, and PV processes)
• Qualified Person for PV (QPPV) and deputy and local safety-responsible representatives (where required under national legislation)
• PV system master file (PSMF)
• Risk management and minimisation systems
• Signal management • Global literature search strategy
• EudraVigilance (EV) maintenance, including Article 57 database

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
David Hukin is the Head of Pharmacovigilance and the PV team at Quanticate. David has a PhD in cell physiology and biophysics and 15 years’ experience in the pharmaceutical industry, with more than 14 years working in the PV sector. He has worked across speciality pharma/biotechnology companies and has gained preand post-marketing experience in a range of therapeutic areas, including gastroenterology, hepatology, neurology, oncology, psychiatric conditions, ATMPs, and orphan drug indication products for rare diseases. Since 2015, David has worked in the specialist PV service provider sector, leading multiple large teams responsible for clinical and post-marketing for customers ranging from small pharma/ biotech to large speciality and generic companies, before joining Quanticate in 2018.
spacer
David Hukin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Restructure Announcement at Illingworth

As a rapidly growing company, Illingworth Research Group (Illingworth) has reflected on its goals, accomplishments and ambitious future growth plans. This has allowed us to consider opportunities for staff to explore their own growth and development possibilities within a rapidly changing landscape. With that in mind, Illingworth are announcing some significant and exciting changes to our organization. Illingworth remain committed to making patient involvement in clinical trials as stress free as possible and our strengthened management team and launch of our patient concierge service, PatientGO, in combination with global, mobile research nursing will ensure as many patients as possible have the chance to participate in the development of critical drugs, regardless of their geography or socioeconomic class.
More info >>

White Papers

The Role of the CRO in Effective Risk-Based Monitoring

Medpace

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >>

 
Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement